Table 1. Characteristics of stem cell transplant recipients studied.
No. of transplants, n | 206 |
---|---|
Median age at transplant, yrs (range) | 27 (3-60) |
Proportion of males (%) | 138 (67 %) |
Indication for transplant | |
Acute Myeloblastic Leukaemia | 61 (30 %) |
Acute Lymphoblastic Leukaemia | 52 (25 %) |
Chronic Myeloid Leukaemia | 30 (15 %) |
Myelodysplastic Syndrome | 16 (8 %) |
Non-Hodgkin’s Lymphoma | 12 (6 %) |
Other Malignant Disordera | 12 (6 %) |
Other Non-malignant Disorderb | 23 (11 %) |
Risk Group | |
Good prognosis | 86 (42 %) |
Poor prognosis | 120 (58 %) |
Donor Type | |
Sibling | 130 (63 %) |
Non-sibling related donor | 8 (4 %) |
Unrelated donor | 68 (33 %) |
HLA Match c | |
6 Antigen match | 183 (89 %) |
Less than 6 antigen match | 21 (10 %) |
Source of Graft d | |
Bone marrow | 141 (68 %) |
Peripheral blood stem cell | 64 (31 %) |
Median CD34 dose ×106/kg recipient weighte (range) | 2.6 (0.2-18.4) |
Type of transplant | |
Reduced intensity conditioning | 12 (6 %) |
Myeloablative | 194 (94 %) |
Pre-transplant conditioning | |
Non radiotherapy based conditioning | 41 (20 %) |
Radiotherapy based conditioning | 165 (80 %) |
Campath In Vivo Usef | |
No Campath in vivo | 105 (51 %) |
Campath-IG in vivo | 44 (21 %) |
Campath-IH in vivo | 52 (25 %) |
Form of Ex vivo T-Cell Depletion | |
No ex vivo T-Cell Depletion | 116 (56 %) |
Campath-IG | 43 (21 %) |
Campath-IH | 40 (19 %) |
CD34 selection | 7 (3 %) |
HCMV serology (recipient/donor)g | |
Neg/Neg | 56 (26 %) |
Neg/Pos | 20 (10 %) |
Pos/Neg | 36 (17 %) |
Pos/Pos | 94 (46 %) |
Idiopathic myelofibrosis, multiple myeloma, sarcoma,
Aplastic anaemia, Fanconi anaemia, thalassaemia major, metachromic leucodystrophy
HLA tissue typing data unavailable in 2 recipient/donor pairs
source of graft unavailable for 1 patient
CD34 dose unavailable in 17 patients
In-vivo Campath use data unavailable in 5 patients
HCMV serology unavailable in 3 recipient/donor pairs